A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

NCT04460820 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Doxorubicin Hydrochloride Liposome Injection

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.